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SUPPLEMENTARY NOTES
ABSTRACT:
We propose that genetic susceptibility to prostate cancer may be in part due to variations in the core circadian genes that regulate circadian rhythms and that serum sex steroid hormone levels modify the effect of circadian gene polymorphisms on prostate cancer risk. Our study is nested within the Prostate Cancer Prevention Trial (PCPT), a randomized placebo-controlled clinical trial to determine if finasteride (an inhibitor of androgen bioactivation) could prevent prostate cancer. In Year 2 of the award, we were approved by the DoD to changed our contracting genotyping facility to the University of Texas Health Science Center at San Antonio (UTHSCSA), which was mandated by the PCPT executive committee, and have been involved in analyzing serum androgen data that will be used for Aim 2 of our study. We have been working with the UTHSCSA to ensure that the genotyping assays for our study using the new genotyping platform will be successful. We have also had the DNA samples re-plated at the PCPT biorepository and shipped to UTHSCSA for genotyping. Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer death in men in the United States yet the only established risk factors for prostate cancer are race, age, and family history [1] . Recent data from observational studies on sleep duration [2] , light at night [3] , rotating shift workers [4, 5] , and male airline pilots [6] [7] [8] suggest that circadian rhythm disruptions increase prostate cancer risk; no underlying molecular mechanism has yet been identified. We propose that genetic susceptibility to prostate cancer may be in part due to variations in genes from a number of pathways including the core circadian genes that regulate circadian rhythms. The goal of this project is to test the novel hypothesis that variants in circadian genes alter the risk of prostate cancer and that serum sex steroid hormone levels modify the effect of circadian polymorphisms on prostate cancer risk. Our study is nested within the Prostate Cancer Prevention Trial (PCPT), a randomized placebocontrolled clinical trial to determine if finasteride (an inhibitor of androgen bioactivation) could prevent prostate cancer. Included in our study are approximately 1,800 case-control pairs (3,600 individuals), for which several biological measurements are available, including serum sex hormone levels, which we will also incorporate into our study to test our hypothesis. Our study has three specific aims, all of which utilizes genotyping data that is to be generated in Award Years 1-2. The second year of the award involved tasks as outlined in the Statement of Work. The following is a report as it pertains to each task in Award Year 2:
SUBJECT TERMS
BODY: This
Task 1 Data management Performance sites: NCI and PCPT Statistical Center Performance period: Months 1-36 (entire period)
We have been in constant communications with the PCPT Statistical Center at the Fred Hutchinson Cancer Research Center (Seattle, WA) since the project's inception. Genotyping data for this project will be incorporated into the PCPT central database as are data from serum androgen assays (completed as part of a separate study but will be used for Aim 2 of this study). With the PCPT Statistical Center, we have completed the analysis on pre-and post-treatment serum androgen levels and prostate cancer risk (supported by a different mechanism). The data on serum androgens and results from the analysis will be used to help guide the analysis for Aim 2 of the study. During the first half of Award Year 2, the PCPT Executive Committee recommended that and subsequently mandated for all genotyping assays for all PCPT sub-studies be performed at the University of Texas Health Science Center at San Antonio (UTHSCSA). This decision was due to the more efficient genotyping platform that was implemented at the UTHSCSA genotyping core facility. We submitted the revision to Task 2 to our DoD contracting officer when the PCPT Executive Committee informed us of their decision and were subsequently given approval for the change in our study. Because of this change, Additional QC work has to be performed before genotyping can begin. First, the DNA samples had to be reconfigured and re-plated to accommodate the new genotyping platform; the DNAs have recently been shipped to UTHSCSA. And second, we had to work with UTHSCSA to ensure that the new genotyping platform will still allow us to genotype the SNPs included in our study. It is anticipated that the genotyping will be completed during the first half of Award Year 3.
Task 3 Monitor quality of genotyping results on an ongoing basis Performance sites: NCI, PCPT Statistical Center Method: Analyses of Hardy-Weinberg equilibrium, inter-individual genotype call rates, concordance of duplicate specimens or known controls, and other quality control (QC) measures. Performance period: Months 7-36
As mentioned above for Task 2, there was a change in genotyping facility (and platform) as mandated by the PCPT Executive Committee. DoD approved this change, and we have been working with UTHSCSA to ensure that the new genotyping platform will allow us to genotype the SNPs included in our study. We have been working with the PCPT Statistical Center on analyzing data related to serum androgen levels as part of the PCPT Program Project; these data were submitted to the PCPT database in mid-2009 and integrated into the PCPT database. Dr. Ann Hsing, the PI of the current award, is leading the analysis and two manuscripts describing the results are in preparation. These data will help guide data analysis necessary to complete Aim 2 of the current study.
Tasks 6 Perform statistical analysis and Task 7 Prepare scientific presentations & manuscripts:
These tasks have been delayed due to the change in genotyping facility as described under Task 2. There are currently no reportable outcomes from this project.
KEY RESEARCH ACCOMPLISHMENTS:
CONCLUSION:
Summarize the results to include the importance and/or implications of the completed research and when necessary, recommend changes on future work to better address the problem. A "so what section" which evaluates the knowledge as a scientific or medical product shall also be included in the conclusion of the report.
